EX-99.02 4 dp08621_ex9902.htm

EXHIBIT 99.02

 
Hampshire International Business Park
Chineham  Basingstoke
Hampshire RG24 8EP
United Kingdom
Tel +44 (0)1256 894000
Fax +44 (0)1256 894708
www.shire.com
 
Press Release
  

 
Notification of major interests in shares

Basingstoke, UK and Philadelphia, US – February 12, 2008– Shire plc (LSE: SHP, NASDAQ: SHPGY, TSX: SHQ), the global specialty biopharmaceutical company,

1. Identity of the issuer or the underlying issuer of existing shares to which voting rights are attached:

Shire plc

2. Reason for the notification
State
Yes/No
An acquisition or disposal of voting rights
 
An acquisition or disposal of financial instruments which may result in the
acquisition of shares already issued to which voting rights are attached
 
An event changing the breakdown of voting rights
Yes
Other (please specify):  
 

3. Full name of person(s) subject to the notification obligation:
Legal & General Group Plc (L&G)
4. Full name of shareholder(s) (if different from 3.):
N/A
5. Date of the transaction (and date on which the threshold is crossed
or reached if different):
N/A
6. Date on which issuer notified:
11 February 2008
7. Threshold(s) that is/are crossed or reached:
Above 5%  (L&G)
8. Notified details:
 


A: Voting rights attached to shares

Class/type of shares
 if possible using the ISIN CODE
Situation previous to
the Triggering
transaction
Resulting situation after the triggering
transaction
 
Number
of
Shares
Number
of
Voting
Rights
Number
of
shares
Number of voting
rights
% of voting
rights
     
Direct
Direct
Indirect
Direct
Indirect
GBP Ord. 0.05
  
Below 5%
29,425,145
26,920,655
2,504,490
4.813
0.447
 
  
 
 
 
 
 
 
ADR Shares
 
 
8,133
21,897
2,502
0.003
0.0004

 
 

 
B: Financial Instruments

Resulting situation after the triggering transaction

Type of financial
instrument
Expiration
date
Exercise/Conversion
Period/ Date
Number of voting
rights that may be
acquired if  the instrument
is exercised/converted
% of voting
rights
 
 
 
 
 


Total (A+B)
  
Number of voting rights
% of voting rights
29,449,544
5.26


9. Chain of controlled undertakings through which the voting rights and/or the financial instruments are effectively held, if applicable:
 
Legal & General Group Plc (Direct and Indirect) (Group)
(29,449,544 – 5.26% = Total Position)
   
Legal & General Investment Management (Holdings) Limited (LGIMH) (Direct and Indirect)
(29,449,544 – 5.26% = Total Position)
   
Legal & General Investment Management Limited (Indirect) (LGIM)
(29,449,544 – 5.26% = Total Position)
 
Legal & General Group Plc (Direct) (L&G) (26,942,552 – 4.81% = LGAS, LGPL & PMC)
   
Legal & General Investment Management (Holdings) Limited
(Direct) (LGIMHD) (21,007,869-3.75% = PMC)
Legal & General Insurance Holdings Limited (Direct) (LGIH)
   
Legal & General Assurance (Pensions Management)
Limited  (PMC) (21,007,869-3.75% = PMC)
Legal & General Assurance Society Limited  (LGAS & LGPL)
   
 
Legal & General Pensions Limited (Direct)  (LGPL)
 
 

 
Proxy Voting:

10. Name of the proxy holder:
N/A
11. Number of voting rights proxy holder will cease to hold:
N/A
12. Date on which proxy holder will cease to hold voting rights:
N/A

13. Additional information:
Notification using the total voting rights figures of 559,283,198
 
14. Contact name:
Helen Lewis (LGIM)
15. Contact telephone number:
020 3124 3851

Contact at Shire plc: Philip Griffin-Smith, Interim Deputy Company Secretary, 01256 894754

For further information please contact:

Investor Relations
Cléa Rosenfeld (Rest of the World)
+44 1256 894 160
 
Eric Rojas (North America)
+1 484 595 8252

Notes to editors
 
SHIRE PLC
 
Shire’s strategic goal is to become the leading specialty biopharmaceutical company that focuses on meeting the needs of the specialist physician.  Shire focuses its business on attention deficit and hyperactivity disorder (ADHD), human genetic therapies (HGT), gastrointestinal (GI) and renal diseases. The structure is sufficiently flexible to allow Shire to target new therapeutic areas to the extent opportunities arise through acquisitions.  Shire’s in-licensing, merger and acquisition efforts are focused on products in niche markets with strong intellectual property protection either in the US or Europe.  Shire believes that a carefully selected portfolio of products with strategically aligned and relatively small-scale sales forces will deliver strong results.
 
For further information on Shire, please visit the Company’s website: www.shire.com.